Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:36 PM
Ignite Modification Date:
2025-12-24 @ 10:36 PM
NCT ID:
NCT01418235
Brief Summary:
Sub-Saharan Africa is the region most affected by the global Human Immunodeficiency Virus (HIV) epidemic. A vaccine is the most promising preventive approach against new HIV infections. The purpose of this study is to evaluate the safety and immunogenicity of 4 experimental preventive HIV vaccine regimens in HIV-uninfected adults in South Africa.
Detailed Description:
The worldwide Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS) epidemic may only be controlled through development and utilization of a safe and effective vaccine that will prevent HIV infection. Due to the high prevalence of HIV-1 subtype C in southern Africa, the South African AIDS Vaccine Initiative (SAAVI), the HIV Vaccine Trials Network (HVTN), Novartis, and the National Institute of Allergy and Infectious Diseases (NIAID) are evaluating three subtype C HIV vaccines, SAAVI DNA-C2, SAAVI MVA-C, and Novartis Subtype C gp140 through this study. These vaccines will be used together in four prime-boost regimens. The SAAVI DNA-C2 vaccine is a multigene deoxyribonucleic acid (DNA) vaccine consisting of two DNA plasmids in equal amounts that express an HIV-1 subtype C polyprotein comprising of Gag-Reverse Transcriptase-Tat-Nef and an HIV-1 subtype C truncated Env. SAAVI MVA-C is a recombinant modified vaccinia Ankara (MVA) vaccine expressing the same immunogens as the SAAVI DNA-C2 vaccine. MVA is a highly attenuated vaccinia virus. The Novartis protein subunit vaccine is a Subtype C oligomeric V2 loop deleted glycoprotein 140 (gp140) vaccine (gp140\[delta\]V2.TV1), given with MF59 adjuvant.
This trial is designed to build upon the Thai RV144 HIV vaccine trial, which demonstrated an efficacy of 31.2% among participants who received a different vaccine regimen of a pox prime followed by a concurrently-administered protein boost. This primary purpose of HVTN 086 is to evaluate the safety and immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Clade C gp140TV1ΔV2 with MF59 adjuvant in various vaccination regimens. The primary analysis will focus on a ranking strategy of the vaccine regimens that is guided by measurements of the immune responses elicited by these vaccines and their respective modes of delivery in various combinations, both sequential and concurrent.
Participants will actively participate in this study for 12 months. Participants will be randomly assigned to receive either a prime-boost preventive vaccine regimen or placebo. Four prime-boost preventive vaccine regimens will be compared; each participant will be randomized to one of 4 groups. Participants in Group 1 will receive MVA-C at months 0 and 1, and gp140/MF59 at months 3 and 6. Group 2 will receive MVA-C and gp140/MF59 at months 1 and 3. Group 3 will receive DNA-C at months 0 and 1, and MVA-C at months 3 and 6. Group 4 will receive DNA-C at months 0 and 1, and both MVA-C and gp140/MF59 at months 3 and 6. Additional study visits will occur at Weeks 2, 6, 13, 14, 26, 28, 36, and 48. All participants will be contacted once annually for 3 years and asked questions about their health. Study procedures include physical exams, blood and urine collection, HIV testing, an electrocardiogram, and questionnaire. Some blood collected from participants will be stored and used in future research. Risk-reduction counseling will be conducted at all study visits.
Study:
NCT01418235
Study Brief:
Protocol Section:
NCT01418235